Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Akito Hata

Showing results (131-140 of 146) with videos related to

Pageof 15
Sort By:
Lung Cancer (Amsterdam, Netherlands)|December 14, 2024
Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort studyJun Sugisaka, Daichi Fujimoto, Motohiro Tamiya, et al.
Lung Cancer (Amsterdam, Netherlands)|September 23, 2024
Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trialRyota Shibaki, Daichi Fujimoto, Eisaku Miyauchi, et al.
JAMA Network Open|February 24, 2023
Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial EligibilityDaichi Fujimoto, Takeshi Morimoto, Motohiro Tamiya, et al.
Nature Communications|March 23, 2025
Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLCKentaro Tanaka, Jun Sugisaka, Yoshimasa Shiraishi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 26, 2023
Tumor Microenvironment Landscape of NSCLC Reveals Resistance Mechanisms for Programmed Death-Ligand 1 Blockade After Chemoradiotherapy: A Multicenter Prospective Biomarker Study (WJOG11518L:SUBMARINE)Koji Haratani, Atsushi Nakamura, Nobuaki Mamesaya, et al.
British Journal of Cancer|March 23, 2024
Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancerKoji Haratani, Atsushi Nakamura, Nobuaki Mamesaya, et al.
ACS Medicinal Chemistry Letters|October 18, 2019
Identification of Novel, Potent, and Orally Available GCN2 Inhibitors with Type I Half Binding ModeJun Fujimoto, Osamu Kurasawa, Terufumi Takagi, et al.
JAMA Oncology|December 21, 2023
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical TrialYoshimasa Shiraishi, Junji Kishimoto, Shunichi Sugawara, et al.
Lung Cancer (Amsterdam, Netherlands)|May 13, 2026
Final overall survival analysis of the APPLE study: atezolizumab and platinum-pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancerYoshimasa Shiraishi, Junji Kishimoto, Shunichi Sugawara, et al.
NPJ Precision Oncology|May 28, 2024
Quantification of cerebrospinal fluid tumor DNA in lung cancer patients with suspected leptomeningeal carcinomatosisTej D Azad, Shigeki Nanjo, Michael C Jin, et al.
Pageof 15

Showing results (131-140 of 146) with videos related to

Sort By:
Pageof 15
Lung Cancer (Amsterdam, Netherlands)|December 14, 2024
Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort studyJun Sugisaka, Daichi Fujimoto, Motohiro Tamiya, et al.
Lung Cancer (Amsterdam, Netherlands)|September 23, 2024
Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trialRyota Shibaki, Daichi Fujimoto, Eisaku Miyauchi, et al.
JAMA Network Open|February 24, 2023
Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial EligibilityDaichi Fujimoto, Takeshi Morimoto, Motohiro Tamiya, et al.
Nature Communications|March 23, 2025
Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLCKentaro Tanaka, Jun Sugisaka, Yoshimasa Shiraishi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 26, 2023
Tumor Microenvironment Landscape of NSCLC Reveals Resistance Mechanisms for Programmed Death-Ligand 1 Blockade After Chemoradiotherapy: A Multicenter Prospective Biomarker Study (WJOG11518L:SUBMARINE)Koji Haratani, Atsushi Nakamura, Nobuaki Mamesaya, et al.
British Journal of Cancer|March 23, 2024
Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancerKoji Haratani, Atsushi Nakamura, Nobuaki Mamesaya, et al.
ACS Medicinal Chemistry Letters|October 18, 2019
Identification of Novel, Potent, and Orally Available GCN2 Inhibitors with Type I Half Binding ModeJun Fujimoto, Osamu Kurasawa, Terufumi Takagi, et al.
JAMA Oncology|December 21, 2023
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical TrialYoshimasa Shiraishi, Junji Kishimoto, Shunichi Sugawara, et al.
Lung Cancer (Amsterdam, Netherlands)|May 13, 2026
Final overall survival analysis of the APPLE study: atezolizumab and platinum-pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancerYoshimasa Shiraishi, Junji Kishimoto, Shunichi Sugawara, et al.
NPJ Precision Oncology|May 28, 2024
Quantification of cerebrospinal fluid tumor DNA in lung cancer patients with suspected leptomeningeal carcinomatosisTej D Azad, Shigeki Nanjo, Michael C Jin, et al.
Pageof 15